At the Pavia center, a study protocol has been recently started with WLL followed by inhaled GM-CSF (Sargramostin) in the treatment of Autoimmune PAP (AIFA FARM7MCPK4). Here, CSF2 is linked to autoimmune pulmonary alveolar proteinosis.